Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Tuberculosis, Multidrug-Resistant Males and females age ≥12 years. Prior to study procedures, if ≥18 years of age, provides informed consent; if <18 years of age, child provides informed assent and has a parent or guardian who provides informed consent on the participant's behalf. 2. Has pulmonary TB based on investigator assessment of all available information (e.g., chest radiograph, sputum smear, culture, molecular testing). 3. Has a sputum sample that is positive for M. tuberculosis that is rifamycin-resistant and fluoroquinolone-susceptible by molecular assay. 4. Is HIV seropositive or seronegative; HIV serostatus must be assessed at screening if either (a) HIV serostatus is unknown, or (b) the last documented negative HIV test was more than two (2) months prior to screening. 5. Willing to attend scheduled follow-up visits and undergo study assessments. 6. Participants of child-bearing potential must agree either (a) to practice an adequate birth control (defined as one of the following oral contraceptives, intrauterine devices, contraceptive implants under the skin, contraceptive rings or patches or injections, diaphragms with spermicide or condoms with foam) or (b) to abstain from heterosexual intercourse during study regimen  Current MTB isolate is known at screening to be fluoroquinolone-resistant. 2. History of allergy (hypersensitivity) or intolerability to one or more agents in the investigational regimens (i.e., Arms 1 and 2) 3. History of serotonin syndrome 4. History of symptomatic ventricular arrhythmia or is taking anti-arrhythmic agents 5. History of optic neuropathy or peripheral neuropathy 6. History of Ehlers-Danlos Syndrome, Marfan Syndrome or aortic aneurism 7. History of prior treatment with delamanid or linezolid for TB for greater than one month. 8. Has at screening received ≥14 days of second-line anti-TB drugs during current TB episode 9. Has at screening a Karnofsky score of ≤40 or, in the opinion of the Investigator, is unlikely to survive 76 weeks. 10. Has at screening laboratory results that meet one or more of the following Hemoglobin concentration <7.0 g/dL (<70 g/L) Platelet count of <80,000/mm3 Absolute neutrophil count (ANC) <2000/ mm3 Serum creatinine >2.0 mg/dL (>177 µmol/L) Serum ALT >3x upper limit of normal (ULN) Total bilirubin >3x upper limit of normal (ULN) Serum albumin <2.8 g/dL (<28 g/L) For women of childbearing potential, a positive or indeterminate serum pregnancy test 11. For women of childbearing potential, has a positive or indeterminate urine pregnancy test on the day of randomization. 12. Has at screening a mean QTcF >450 msec based on three ECGs. 13. At screening requires ongoing use of prohibited drugs indicated in section 4.2 14. At screening, has weight less than 33 Kg